Research Suggests That Single Dose of Psychedelics May Alleviate Racial Injustice Trauma

A recent study has suggested that one positive experience on a psychedelic medicine may help alleviate anxiety, depression and stress symptoms in Indigenous and Black people as well as people of color who have been affected by racism.

The retrospective study involved 30 participants who admitted that in the 30 days following an experience with either ecstasy (“MDMA”), psilocybin mushrooms or LSD, the trauma-related symptoms they experienced that were connected with acts of racism were reduced.

Ohio State University assistant professor of social work Alan Davis, who was also a co-lead author of the study, explained that the participants’ experience with the psychedelic substances was so strong that they could recollect and report on the changes in their racial trauma symptoms.

Generally, the study also demonstrated that the more insightful and spiritual a participant’s psychedelic experience was, the more notable the recollected decreases in symptoms related to their trauma were. Alan Davis collaborated on this study with University of Ottawa’s Canada research chair in Mental Health Disparities, Monnica Williams.

Williams stated that at the moment, no treatments exist that are backed by empirical data that caters to racial trauma in particular. This is why the study is important — it demonstrates that psychedelic drugs can be an important approach to enable healing.

The study sample was made up of adults who identified as Hispanic, Pacific Islander, Asian, Black, Native Hawaiian and Native American/Indigenous Canadian. The participants involved in the study were recruited through the use of a research panel by Qualtrics survey from both Canada and the United States. The total number of participants was 313, all of whom admitted to having consumed a dose of a psychedelic substance in the past, adding that they believed the psychedelic had provided them with relief from the effects of racial discrimination.

The study participants then completed questionnaires that collected information on their past experiences with mental health symptoms, psychedelic use and racial trauma after enrollment. In addition, they were asked to remember a psychedelic experience they deemed memorable as well as its enduring and short-term effects. They were then asked to recollect the gravity of their symptoms of stress, depression and anxiety that were connected to exposure to racial injustices in the 30 days before and after the experience with psychedelic substances.

Apart from assessing the data collected above, the researchers also evaluated symptoms linked to PTSD related to discrimination.

All the participants reported that their symptoms of stress, depression and anxiety after their psychedelic experience were lower than before they had used the psychedelic substance. It seems the psychedelics’ positive effects influenced their symptom reduction.

The study was reported online in the “Drugs: Education, Prevention and Policy” journal.

The world is waking up to the immense potential of psychedelics as a medicine and a number of companies are taking position to ride this wave of reawakening. One such firm is Pure Extracts Technologies Corp. (CSE: PULL), which is riding on its vast experience as a cannabis extraction company to pivot to developing therapeutic psychedelic products as well as functional mushroom products.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) are available in the company’s newsroom at https://ibn.fm/PULL

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.